Search Results - "Hovey, Elizabeth J."

The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET) by Field, Kathryn M., Phal, Pramit M., Fitt, Greg, Goh, Christine, Nowak, Anna K., Rosenthal, Mark A., Simes, John, Barnes, Elizabeth H., Sawkins, Kate, Cher, Lawrence M., Hovey, Elizabeth J., Wheeler, Helen

“…BACKGROUND Bevacizumab has been associated with prolonged progression‐free survival for patients with recurrent glioblastoma; however, not all derive a…”
Get full text

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma by Kong, Benjamin Y, Sim, Hao-Wen, Barnes, Elizabeth H, Nowak, Anna K, Hovey, Elizabeth J, Jeffree, Rosalind, Harrup, Rosemary, Parkinson, Jonathon, Gan, Hui K, Pinkham, Mark B, Yip, Sonia, Hall, Merryn, Tu, Emily, Carter, Candace, Koh, Eng-Siew, Lwin, Zarnie, Dowling, Anthony, Simes, John S, Gedye, Craig

“…IntroductionGlioblastoma (GBM) is the most common malignant primary central nervous system cancer in adults. The objective of the Multi-Arm GlioblastoMa…”
Get full text

Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial by Hovey, Elizabeth J, Field, Kathryn M, Rosenthal, Mark A, Barnes, Elizabeth H, Cher, Lawrence, Nowak, Anna K, Wheeler, Helen, Sawkins, Kate, Livingstone, Ann, Phal, Pramit, Goh, Christine, Simes, John

“…Abstract Background In patients with recurrent glioblastoma, the benefit of bevacizumab beyond progression remains uncertain. We prospectively evaluated…”
Get full text

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma by Field, Kathryn M, Simes, John, Nowak, Anna K, Cher, Lawrence, Wheeler, Helen, Hovey, Elizabeth J, Brown, Christopher S B, Barnes, Elizabeth H, Sawkins, Kate, Livingstone, Ann, Freilich, Ron, Phal, Pramit M, Fitt, Greg, Rosenthal, Mark A

“…The optimal use of bevacizumab in recurrent glioblastoma (GBM), including the choice of monotherapy or combination therapy, remains uncertain. The purpose of…”
Get full text

Barriers to managing sleep disturbance in people with malignant brain tumours and their caregivers: a qualitative analysis of healthcare professionals’ perception by Jeon, Megan S., Agar, Meera R., Koh, Eng-Siew, Nowak, Anna K., Hovey, Elizabeth J., Dhillon, Haryana M..

“…Purpose This study explores healthcare professionals (HCPs)’ perception and current management of sleep disturbance (SD) in people with malignant brain tumours…”
Get full text

Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy by Mizrahi, David, Goldstein, David, Trinh, Terry, Li, Tiffany, Timmins, Hannah C., Harrison, Michelle, Marx, Gavin M., Hovey, Elizabeth J., Lewis, Craig R., Friedlander, Michael, Park, Susanna B.

“…Aim There are many barriers to physical activity among cancer survivors. Survivors treated with neurotoxic chemotherapy may develop chemotherapy‐induced…”
Get full text

LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study by Kong, Benjamin Y, Sim, Hao-Wen, Nowak, Anna K, Yip, Sonia, Barnes, Elizabeth H, Day, Bryan W, Buckland, Michael E, Verhaak, Roel, Johns, Terrance, Robinson, Cleo, Thomas, Marc A, Giardina, Tindaro, Lwin, Zarnie, Scott, Andrew M, Parkinson, Jonathon, Jeffree, Rosalind, Lourenco, Richard de Abreu, Hovey, Elizabeth J, Cher, Lawrence M, Kichendasse, Ganessan, Khasraw, Mustafa, Hall, Merryn, Tu, Emily, Amanuel, Benhur, Koh, Eng-Siew, Gan, Hui K

“…IntroductionGrades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3…”
Get full text

Understanding sleep disturbance in the context of malignant brain tumors: a qualitative analysis by Jeon, Megan S, Agar, Meera R, Koh, Eng-Siew, Nowak, Anna K, Hovey, Elizabeth J, Dhillon, Haryana M

“…Abstract Background Sleep is an important element in health-related quality of life of cancer patients and caregivers. This study aimed to explore the…”
Get full text

NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma by Sim, Hao-Wen, Wachsmuth, Luke, Barnes, Elizabeth H, Yip, Sonia, Koh, Eng-Siew, Hall, Merryn, Jennens, Ross, Ashley, David M, Verhaak, Roel G, Heimberger, Amy B, Rosenthal, Mark A, Hovey, Elizabeth J, Ellingson, Benjamin M, Tognela, Annette, Gan, Hui K, Wheeler, Helen, Back, Michael, McDonald, Kerrie L, Long, Anne, Cuff, Katharine, Begbie, Stephen, Gedye, Craig, Mislang, Anna, Le, Hien, Johnson, Margaret O, Kong, Benjamin Y, Simes, John R, Lwin, Zarnie, Khasraw, Mustafa

“…Abstract Background There is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented in prior…”
Get full text

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges by Rahmathulla, Gazanfar, Hovey, Elizabeth J, Hashemi-Sadraei, Neda, Ahluwalia, Manmeet S

“…High-grade gliomas continue to have dismal prognosis despite advances made in understanding the molecular genetics, signaling pathways, cytoskeletal dynamics,…”
Get full text

Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial by Field, Kathryn M., Fitt, Greg, Rosenthal, Mark A., Simes, John, Nowak, Anna K., Barnes, Elizabeth H., Sawkins, Kate, Goh, Christine, Moffat, Bradford A., Salinas, Simon, Cher, Lawrence, Wheeler, Helen, Hovey, Elizabeth J., Phal, Pramit M.

“…Aim Assessment of magnetic resonance imaging (MRI) in glioblastoma can be challenging. For patients with recurrent glioblastoma managed on the CABARET trial,…”
Get full text

A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET) by Field, Kathryn Maree, Simes, John, Wheeler, Helen, Hovey, Elizabeth J., Nowak, Anna K., Cher, Lawrence, Brown, Chris, Livingstone, Ann, Sawkins, Kate, Rosenthal, Mark

“…Abstract only 2017 Background: The optimal use of bevacizumab (bev) in recurrent glioblastoma (GBM) remains uncertain including the choice between monotherapy…”
Get full text

A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype by Jue, Toni Rose, Olafson, Lauren R, Siddell, Anna H, Rapkins, Robert W, Ng, Benedict, Yin, Julia X M, Lu, Victor M, Chung, Sylvia A, Whittaker, Shane P, Davies, Matthew, Fairhall, Jacob M, Hovey, Elizabeth J, McDonald, Kerrie L

“…Effective treatments that extend survival of malignant brain tumor glioblastoma (GBM) have not changed in more than a decade; however, there exists a minority…”
Get full text

Geriatric assessment of older patients with cancer in Australia—A multicentre audit by Lakhanpal, Roopa, Yoong, Jaclyn, Joshi, Sachin, Yip, Desmond, Mileshkin, Linda, Marx, Gavin M, Dunlop, Tracey, Hovey, Elizabeth J, Della Fiorentina, Stephen A, Venkateswaran, Lakshmi, Tattersall, Martin H.N, Liew, Sem, Field, Kathryn, Singhal, Nimit, Steer, Christopher B

“…Abstract Objective The aim of this study is to determine the frequency of geriatric assessment in patients aged over 70 years in Australian medical oncology…”
Get full text

Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy: 1296 by Mizrahi, David, Goldstein, David, Trinh, Terry, Li, Tiffany, Timmins, Hannah C., Harrison, Michelle, Marx, Gavin M., Hovey, Elizabeth J., Lewis, Craig R., Friedlander, Michael, Park, Susanna B.

Get full text

Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy: 1296 by Mizrahi, David, Goldstein, David, Trinh, Terry, Li, Tiffany, Timmins, Hannah C., Harrison, Michelle, Marx, Gavin M., Hovey, Elizabeth J., Lewis, Craig R., Friedlander, Michael, Park, Susanna B.

Get full text

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma by Conduit, Ciara, Kichenadasse, Ganessan, Harris, Carole A., Gurney, Howard, Ferguson, Tom, Parnis, Francis, Goh, Jeffrey C., Morris, Michelle Frances, Underhill, Craig, Pook, David William, Davis, Ian D., Roncolato, Felicia, Harrison, Michelle L., Begbie, Stephen, Joshua, Anthony M., Link, Emma, Hovey, Elizabeth J., Gedye, Craig

“…4537 Background: Immune checkpoint immunotherapy (ICI) is active against many cancers. Many people are failed by PD1 inhibition alone, but not all patients…”
Get full text

Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma by Gedye, Craig, Pook, David William, Krieger, Laurence Eliot Miles, Harris, Carole A., Goh, Jeffrey C., Kichenadasse, Ganessan, Gurney, Howard, Underhill, Craig, Parnis, Francis, Joshua, Anthony M., Ferguson, Tom, Roncolato, Felicia, Harrison, Michelle L., Begbie, Stephen, Morris, Michelle Frances, Hovey, Elizabeth J., George, Mathew, Prithviraj, Prashanth, Link, Emma, Davis, Ian D.

“…Abstract only 4565 Background: Immunotherapy targeting PD1 is active across many cancers, but many people are failed by PD1 inhibition alone. UNISON (ANZUP…”
Get full text

UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy by Gedye, Craig, Pook, David William, Krieger, Laurence Eliot Miles, Harris, Carole A., Goh, Jeffrey C., Kichenadasse, Ganessan, Gurney, Howard, Underhill, Craig, Parnis, Francis, Joshua, Anthony M., Ferguson, Tom, Roncolato, Felicia, Harrison, Michelle L., Begbie, Stephen, Morris, Michelle Frances, Hovey, Elizabeth J., George, Mathew, Prithviraj, Prashanth, Liow, Elizabeth Chien Hern, Davis, Ian D.

“…Abstract only 325 Background: Immune checkpoint inhibitors (ICI) are active in many cancers, but people with rare variant, non clear-cell renal cell carcinoma…”
Get full text

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502) by Weickhardt, Andrew James, Foroudi, Farshad, Lawrentschuk, Nathan, Galleta, Laura, Seegum, Amanda, Herschtal, Alan, Link, Emma, McJannett, Margaret Mary, Liow, Elizabeth Chien Hern, Grimison, Peter S., Zhang, Alison Yan, Patanjali, NItya, Ng, Siobhan, Goodwin, Robert, Tang, Colin, Chen, Colin, Hovey, Elizabeth J., Hruby, George, Guminski, Alexander David, Davis, Ian D.

“…Abstract only 485 Background: In patients (pts) with muscle invasive bladder (MIBC) suitable for curative definitive chemoradiotherapy (CRT), we hypothesise…”
Get full text